Modality
Vaccine
MOA
HPK1i
Target
CD123
Pathway
Proteasome
CeliacMyelofibrosisCrohn's
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
Aug 2017
→ Apr 2030
NDA/BLACurrent
NCT04872630
2,062 pts·Myelofibrosis
2017-08→2030-04·Recruiting
NCT04564474
2,337 pts·Myelofibrosis
2022-08→2027-07·Not yet recruiting
4,399 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-07-071.3y awayPh3 Readout· Myelofibrosis
2030-04-144.0y awayPh3 Readout· Myelofibrosis
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-07-07 · 1.3y away
Myelofibrosis
Ph3 Readout
2030-04-14 · 4.0y away
Myelofibrosis
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04872630 | NDA/BLA | Myelofibrosis | Recruiting | 2062 | ACR20 |
| NCT04564474 | NDA/BLA | Myelofibrosis | Not yet recr... | 2337 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |